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Abstract. Antisera raised to a detergent- and salt-resis- 
tant matrix fraction from rat liver Golgi stacks were 
used to screen an expression library from rat liver 
cDNA. A  full-length clone was obtained encoding a 
protein of 130 kD (termed GM130), the COOH-termi- 
nal domain of which was highly homologous to a Golgi 
human auto-antigen, golgin-95 (Fritzler et al., 1993). 
Biochemical data showed that GM130 is a peripheral 
cytoplasmic protein that is tightly bound to Golgi mem- 
branes and part of a larger oligomeric complex. Predic- 
tions from the protein sequence suggest that GM130 is 
an extended rod-like protein with coiled-coil domains. 
Immunofluorescence microscopy showed partial over- 
lap with medial- and trans-Golgi  markers but almost 
complete overlap with the cis-Golgi network (CGN) 
marker, syntaxin5. Immunoelectron microscopy con- 
firmed this location showing that most of the GM130 
was located in the CGN and in one or two cisternae on 
the cis-side of the Golgi stack. GM130 was not re-dis- 
tributed to the ER in the presence of brefeldin A  but 
maintained its overlap with syntaxin5 and a partial 
overlap with the ER-Golgi intermediate compartment 
marker, p53. Together these results suggest that 
GM130 is part of a cis-Golgi matrix and has a role in 
maintaining cis-Golgi structure. 
T 
HE  Golgi apparatus  receives the  entire output of 
newly-synthesized proteins from the ER. They en- 
ter at the cis or entry face, in a compartment termed 
the cis-Golgi network (CGN)  ~ which can be thought of as 
the last quality control step on the pathway (Huttner and 
Tooze, 1989; Pelham, 1991). Only properly folded proteins 
are allowed to proceed on to the stacked cisternae (Hurt- 
ley and Helenius, 1989) where posttranslational modifica- 
tions are carried out, most notably to the bound oligosac- 
charides  (Roth,  1987).  When  they reach  the  TGN,  the 
proteins are sorted to their correct destination (Griffiths 
and Simons, 1986). 
Considerable progress has been made in identifying the 
proteins involved in the vesicle machinery responsible for 
conveying cargo from one compartment to the next (Pryer 
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et al.,  1992;  Rothman,  1994). The same  is  also  true for 
those enzymes that carry out the posttranslational modifi- 
cations. Many have now been sequenced and the signals 
that determine their precise location within the Golgi ap- 
paratus  are being investigated (see Nilsson and Warren, 
1994). 
Much less progress has been made in identifying struc- 
tural proteins responsible for the unique  architecture of 
the  Golgi apparatus.  Morphological studies  have  shown 
that there are structures in the space between the cisternae 
that might be involved in cisternal stacking (Franke et al., 
1972; Mollenhauer, 1965; Mollenhauer et al.,  1973; Cluett 
and Brown, 1992). Each Golgi apparatus is also embedded 
in a "zone of exclusion" containing many fibriUar structures 
(Mollenhauer and Morr6, 1978). It is not, however, clear 
to what extent these structures can be matched to the in- 
creasing  number  of cytoplasmic  proteins  that  are  now 
known to be associated with the Golgi apparatus. 
These proteins are of several types. There are those that 
interact with the classical cytoskeleton or are homologues 
of it. Comitin, an aetin-binding protein, has been localized 
to the periphery of the  Golgi apparatus  and may be in- 
volved in tethering the organelle to the actin cytoskeleton 
(Weiner et al.,  1993). A  homologue of the erythrocyte 
[3-spectrin has been localized to the Golgi apparatus (Beck 
et al., 1994b) as well as a homologue of ankyrin (Beck et 
al., 1994a). Given the role of the parental proteins in main- 
taining the structure of the erythrocyte, these homologues 
might be involved in maintaining the structural integrity of 
the Golgi apparatus. 
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autoantigens.  Most  are  autoantigens  found in  Sjrgren's 
syndrome, and comprise a  230-kD protein found on the 
trans side of the Golgi apparatus (Kooy et al., 1992), a 210- 
kD protein found on the cis side (Rios et al., 1994) and two 
other proteins (golgin-95 and golgin-160) which are associ- 
ated with the Golgi apparatus though the precise location 
is still unclear (Fritzler et al., 1993). The sequences of both 
golgin-95 and golgin-160 have been determined and reveal 
a high content of heptad repeats suggesting a rodlike struc- 
ture (Fritzler et al., 1993). 
Giantin/GCP372 is also an autoantigen found in rheu- 
matoid arthritis. It has a  high content of heptad repeats 
and a molecular weight in excess of 350 kD (Linstedt and 
Hauri, 1993; Seelig et al., 1994; Sohda et al., 1994). Unlike 
the other autoantigens found so far it is a membrane pro- 
tein that is anchored by a  COOH-terminal spanning do- 
main. It has been suggested that this protein might be in- 
volved in cisternal stacking, but immunoelectron microscopy 
(immuno-EM) indicates that most of the protein surrounds 
the Golgi stacks (Seelig et al., 1994). It is, therefore, more 
likely to act as a tethering or positioning device. 
Our approach to identifying structural proteins of the 
Golgi has been to prepare a detergent- and salt-resistant 
matrix from highly purified rat liver Golgi stacks (Slusare- 
wicz et al., 1994b). One property of this matrix is the ca- 
pacity to bind medial-/trans-Golgi enzymes with high affin- 
ity. Since these enzymes are present throughout individual 
Golgi cisternae and the binding is sensitive to prior treat- 
ment with proteases, this suggests that at least part of this 
matrix is present within the intercisternal space. 
Here we have used an antiserum to this matrix to screen 
an expression library and describe the properties of a 130- 
kD  protein (termed GM130 for Golgi matrix protein of 
130 kD) which is related to golgin-95 and may be a  new 
family member. 
Materials and Methods 
Materials 
All reagents were of analytical grade or higher and purchased from either 
Sigma Chemical Co. (St. Louis, MO) or BDH Ltd. (Poole, UK) unless 
otherwise stated. 
Isolation of the Golgi  Matrix Fraction 
The Golgi matrix fraction was prepared from purified rat liver Golgi mem- 
branes as described previously (Slusarewicz et al., 1994a,b).  Briefly, puri- 
fied rat liver Golgi membranes were suspended in Triton buffer (2% [wt/ 
vol] Triton X-100,  50 mM MOPS-NaOH, pH 7.0, 0.1 mM MgC12, 1 mM 
dithiothreitol, 10% [wt/vol] sucrose) to 1 mg/ml protein, incubated on ice 
for 30 min, and then centrifuged at 15,000 g for 30 min at 4°C. The Triton 
pellet was isolated, suspended in the same volume of Triton buffer con- 
taining 150 mM NaCI, incubated on ice for 30 min, and then again centri- 
fuged at 15,000 g for 30 min at 4°C to yield the Golgi matrix fraction. 
Antisera 
Antisera to the Golgi matrix fraction were raised in rabbits by immunizing 
and boosting with 80-160 ~g protein in Freund's adjuvant as described 
previously (Kreis, 1986). 25 ml of blood was collected from immunized an- 
imals 12-14 d after boosting and repeated up to six times at weekly intervals. 
Rabbit antisera to recombinant GM130 were raised against two over- 
lapping regions of the protein. The first was a 17-kD fragment (amino ac- 
ids 322 to 471; nucleotides 1200 to 1651) fused with 13-galaetosidase in the 
pUEX plasmid. Inclusion bodies were isolated and used for immuniza- 
tion. The second was a 97-kD fragment (amino acids 194 to 912; nucle- 
otides 817 to 2977)  expressed using the QIA express system (QIAGEN 
Inc., Chatsworth, CA) following the manufacturer's protocol. The NH2- 
terminal His6 tag was used to purify the recombinant protein which was 
then used for immunization. Affinity purification of the antibody was per- 
formed using the same recombinant proteins after coupling to Thiopropyl 
Sepharose 6B (Pharmacia Biotech, Uppsala, Sweden) following the man- 
ufacturer's protocol as described by Harlow and Lane (1988). 
cDNA Cloning 
Anti-Golgi matrix serum was used to screen a rat liver cDNA library that 
was constructed in the expression plasmid, pUEX1 (Luzio et al., 1990). 
Expression of clones, antibody screening and purification of the fusion 
proteins was performed as previously described (Brake et al., 1990; Stan- 
ley and Luzio, 1984). A 452-bp cDNA fragment (17-kD fragment, nucle- 
otide 1200 to 1651; Fig. 3 A) and a 3,464-bp cDNA fragment (the 3.5-kbp 
fragment or 97- kD fragment; Figs. 2 A and 3 A) were obtained by screen- 
ing. Poly A + RNA was isolated from rat (Sprague-Dawley) liver and used 
for 5'-rapid  amplification of cDNA  end (RACE)  using the 5'-Ampli- 
FINDER RACE Kit (CLONTECH, Palo Alto, CA) following the manu- 
facturer's  protocol.  Gene  specific  primers  used  were  5'-GGAGCT- 
GTTTCAGTGACTCCATCAGCTGG-3'  (Fig. 3 A, #1)  for first strand 
synthesis  and  5'-CCATGGCCTGTFGCAACTGCTCATTACTGC-3' 
(Fig. 3 A, #2) for polymerase chain reaction. 
In Vitro Transcriptionltranslation 
A  full-length plasmid was constructed by combining the EeoRI-BsrGI 
fragment from the 5'-RACE product  and the BsrGI-BamHI fragment 
from the 3.5-kbp cDNA fragment and cloning into Bluescript II KS+ 
(Stratagene, La Jolla, CA). Coupled in vitro transcription and translation 
was performed using the TNT T3  coupled Reticulocyte Lysate System 
(Promega Corp., Madison, WI), a sample was solubilized in SDS-PAGE 
sample buffer and analysed by Western blotting using antiserum against 
the 17-kD fragment of GM130. 
DNA Sequence Analysis 
The cDNA sequence was determined in both directions by appropriately 
synthesized oligonucleotide primers. The hydropathy plot was performed 
according to the method of Kyte and Doolittle (1982). Coiled-coil predic- 
tion was performed according to the method of Lupas et aL (1991). 
Western Blotting 
This was performed as described previously (Misteli and Warren, 1994). 
Ceils were lysed using SDS-PAGE sample buffer without dye and dithio- 
threitol. Other proteins were precipitated before fractionation by SDS- 
PAGE using a 6% or 6-15% gradient gel. After transfer to a nitrocellu- 
lose membrane (Hybond-C super; Amersham International plc, UK) the 
blots were probed with antibodies to the Golgi matrix, GM130 (17- and 
97-kD fragment) and cd,3-1,6-mannosidase II (Man II)  (Moremen and 
Touster, 1985) at a dilution of 1:1,000. Goat anti-rabbit antibody conju- 
gated to HRP (Biosouree International, Camarillo, CA) was used as a sec- 
ondary antibody at 1:1,000 dilution and this was visualized using the ECL 
system (Amersham). Protein was assayed using the BCA protein assay re- 
agent (Pierce, Rockford, IL). 
Quantitation of GM130 
Samples were fracfionated by SDS-PAGE in parallel with serially diluted, 
total Golgi membrane lysates to provide an internal standard curve. The 
x-ray film was scanned by an Imagestore 5000 system (Ultra Violet Prod- 
ucts Ltd., Cambridge, UK) and the intensity of each band was extracted 
using the NIH image program, version 1.56 (Wayne Rasband, NIH, Be- 
thesda, MD). 
Extraction of Golgi Membranes 
All extraction buffers contained protease inhibitors (1 ~g/ml aprotinin, 1 
ixg/ml leupeptin, 1 i~g/ml pepstatin, 1 ixg/ml antipain, 1 i~g/ml chymostatin, 
1 mM benzamidine, and 1 mM PMSF). Purified Golgi membranes (100 
I~g) were suspended in 100  I~1 of phosphate buffer (100  mM potassium 
phosphate buffer, pH 6.7, 5 mM MgC12, and 0.25 M sucrose), 1 M KCI in 
phosphate buffer, 0.2  M  sodium carbonate, or 6 M  urea  in phosphate 
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4°C,  100,000 g for 10 min to pellet the membranes. Triton X-114 extrac- 
tion was performed as described by Bordier (1991)  with slight modifica- 
tions. Briefly, purified Golgi membranes (100 ~g) were suspended in 100 
t~1 of buffer containing 1% (wt/vol) Triton X-114, 100 mM potassium phos- 
phate buffer, pH 6.7 and 5 mM MgC12, incubated on ice for 10 rain, and 
centrifuged at 4°C, 1,700 g for 5 rain to remove insoluble aggregates. The 
supernatant was recovered and condensed at 37°C for 3 min and centri- 
fuged at 1,700 g for 5 min to separate the aqueous and detergent phases. 
Protein was precipitated by the method of Wessel and Flugge (1984),  and 
analyzed by Western blotting after SDS-PAGE. 
Chymotrypsin Treatment of Golgi Membranes 
Purified Golgi membranes (100 p.g) were suspended in 90 p,1 of phosphate 
buffer (100 mM potassium phosphate buffer, pH 6.7, 5 mM MgCI~, and 
0.25  M sucrose), 10 pJ of chymotrypsin (0, 2.5, 5,  10 mg/ml) was added, 
and incubated on ice for 30 min. Then, 1 }xl of 0.2 M PMSF was added to 
neutralize the chymotrypsin and membranes were pelleted at 100,000 g for 
10 min at 4°C. Protein was precipitated and analyzed by Western blotting 
after SDS-PAGE as described above. 
Man H Assay 
Man II was assayed spectrophotometrically as described by Bischoff and 
Kornfeld (1984)  except that the concentration of the substrate, p-nitro- 
phenyl-a-D-mannopyranoside, was 2 mM in 100 mM sodium phosphate, 
pH 6.0. The assay was carried out at 37°C for 1 h. 
Gel Filtration 
The Triton pellet, isolated from 10 mg of purified Golgi membranes as de- 
scribed above, was incubated with 500 ~1 of Triton buffer containing 500 
mM NaCI for 30 min on ice, then centrifuged at 15,000 g for 30 rain at 4°C. 
The supernatant was applied onto a Superose 6 column (1-cm diam, 30-cm 
height; Pharmacia Biotech) equilibrated with Triton buffer containing 500 
mM NaC1 and 0.1%  (wt/vol) Triton X-100, and 1-ml fractions were col- 
lected. Protein was precipitated and analyzed by Western blotting after 
SDS-PAGE as described above. 
Cell Culture and BFA Treatment 
HeLa and NRK cells were grown in Dulbecco's modified eagle medium 
(Life Technologies Inc., Gaithersburg, MD) supplemented with 10% FCS 
(Life Technologies Inc.) whereas HeLa cells expressing myc-tagged 13-1,2- 
N-acetylglucosaminyltransferase I (NAGT I) (Nilsson et al, 1993) and ve- 
sicular stomatitis virus glycoprotein (VSV-G) tagged a2,6-sialyltransferase 
(SialylT)  (Rabouille et al., 1995) were grown in Dulbecco's modified eagle 
medium supplemented with 10% FCS and 200 txg/ml geneticin (Life Tech- 
nologies Inc.). 
The cDNA encoding rat syntaxin 5 (GenBank/EMBL/BBBJ accession 
No. L20822)  with a myc epitope engineered into the NH  2 terminus (Ban- 
field et al., 1994) was cloned into the pSRct vector and stable lines gener- 
ated  and  maintained  in  HeLa  cells as  described (Nilsson et  al.,  1993; 
Rabouille et al., 1995). 
Cells were plated on coverslip for 24 h before treatment with 200 p.g/ml 
BFA for 30 min (Epicentre, Madison, WI). 
Immunofluorescence Microscopy 
Cells were fixed with 3 % paraformaldehyde and permeabilized with 0.1% 
Triton X-100 as described previously (Louvard et al., 1982; Nilsson et aL, 
1994). Affinity purified rabbit antibody for GM130 (17-kD fragment) was 
used for double labeling the ceils together with mouse monoclonal antibod- 
ies for the myc epitope (9El0; Evan et al., 1985), the VSV-G epitope (P5D4; 
Kreis and Lodish, 1986; Soldati and Perriard, 1991), or p53 (Schweizer et al., 
1988). Goat anti-rabbit antibodies and goat anti-mouse antibodies conju- 
gated to Texas red or FITC (Biosource International, Camarillo, CA) were 
used to visualize the primary antibodies. Ceils were visualized using a Bio- 
Rad MRC-1000 Laser scanning confocal Imaging system (Bio-Rad Labo- 
ratories, Richmond, CA). 
Immuno-EM 
Cells were fixed in a mixture of 2% paraformaldehyde and 0.2% glutaral- 
dehyde in 0.2 M phosphate buffer, pH 7.4, and cut as described previously 
(Rabouille et al, 1995). Sections of NRK cells were incubated with affin- 
ity purified polyclonal antibodies to the 97-kD fragment of GM130 fol- 
lowed by goat anti-rabbit antibodies coupled to 10 nm gold particles. Sec- 
tions of the HeLa cells expressing VSV-G-tagged SialylT (Rabouille et 
al., 1995) were incubated with a mixture of rabbit anti-97-kD fragment an- 
tibodies and a mouse monoclonal antibody (P5D4) to the VSV-G epitope 
on the SialylT.  This was followed by goat anti-rabbit antibodies coupled 
to 10 nm gold particles and then by goat anti-mouse antibodies coupled to 
5  nm gold particles. Samples were  examined at  80  kV using a  Philips 
CM10 electron microscope. 
The labeling for SialylT was used to determine the polarity and GM130 
was assigned to the cis or trans side according to an imaginary line that bi- 
sected each stack of cisternae. 
Results 
Cloning of GM130 
Rat liver Golgi membranes were purified 150-fold over ho- 
mogenate (using ~31,4-galactosyltransferase as the marker) 
and then extracted sequentially with 2% Triton X-100 and 
150 mM NaC1. The insoluble pellet, the Golgi matrix frac- 
tion,  was  used  to  raise  polyclonal  antisera  which  were 
screened by immunofluorescence microscopy. One antise- 
rum, which gave a particularly striking Golgi staining pat- 
tern was chosen for further analysis by Western blotting 
after fractionation  of Golgi membranes  by SDS-PAGE 
and the results are shown in Fig. 1. This antiserum only de- 
tected a few proteins in purified rat liver Golgi membranes, 
Figure 1.  Western blotting using 
anti-matrix and anti-GM130 an- 
tisera.  Purified  rat  liver  Golgi 
membranes  (17.4  ~tg/lane)  were 
fractionated on a 6% SDS-poly- 
acrylamide gel and Western blot- 
ted using antibodies either to the 
Golgi matrix fraction (lane 1) or 
GM130 (lane 2). The anti-matrix 
antiserum  recognized  proteins 
of 130,  120  and  100 kD  (lane  1, 
dots  on  the  left)  whereas  the 
anti-GM130  antiserum  recog- 
nized  a  major  band  at  130kD 
and a likely proteolytic fragment 
at  116kD  (lane  2,  dots  on  the 
right).  Molecular  weight  mark- 
ers are shown on the left. 
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Figure 2.  Construction  and transcription/translation  of the full- 
length cDNA encoding  GM130. (A) The longest clone encoding 
GM130 was 3.5 kbp in length and comprised an incomplete cod- 
ing region (2,161 bp, shaded area) followed by 1,303 bp of non- 
coding 3' sequence. The missing 5' sequence  was obtained using 
the  5'-RACE protocol.  Both  fragments were linked  using  the 
BsrGI site to construct the full length fragment (see Material  and 
Methods).  (B) Coupled transcription/translation  in the absence 
(lane 2) or presence (lane 3) of the full-length  cDNA encoding 
GM130. Samples were fractionated by 6% SDS-polyacrylamide 
gel and Western blotted using antiserum to a 17-kD fragment of 
GM130. Note that the translated  product (lane 3) had exactly the 
same molecular weight as the GM130 in rat liver Golgi membranes 
(lane 1). Molecular weight markers are shown on the left. (C) Ly- 
sates (100 Ixg) of NRK (lanes I  and 3) and HeLa (lanes 2 and 4) 
cells were fractionated by 6% SDS-polyacrylamide  gel and West- 
ern blotted using affinity-purified  polyclonal  antibodies  to a 17- 
(lanes 1 and 2) or a 97-kD fragment (lanes 3 and 4) of GM130. 
Both antibodies  recognized a 130-kD protein (large arrowheads) 
and  minor  lower  molecular  weight  proteins  with  molecular 
weight of 120, 116, 83, and 80 kD (small arrowheads). Molecular 
weight markers are shown on the left. 
the most prominent having molecular weights of 130,  120, 
and 100 kD (Fig. 1, lane 1). 
This antiserum was then used to screen a rat liver cDNA 
library in pUEX1 expression plasmid (Luzio et al., 1990). 
5  X  105 clones were screened and ten positives were iso- 
luted. These were grouped into three classes on the basis 
of their  sequence  and  a  recombinant  protein  from each 
class was used to raise polyclonal antisera.  Antisera to a 
17-kD fragment in one of these classes recognized the up- 
permost 130-kD protein identified using the original anti- 
serum and a likely proteolytic fragment of 116 kD (Fig. 1, 
lane 2). This protein, GM130, was chosen for further study. 
The longest cDNA clone encoding GM130 was 3.5 kbp 
in length. This was significantly shorter than the 5-kb mRNA 
encoding GM130 characterized by Northern blotting (data 
not shown) showing that sequence at the 5' and/or 3' end 
was missing. Sequence analysis predicted an open reading 
frame of 2,161  bp (720 amino acids giving a calculated mo- 
lecular weight of 82 kD), followed by 1,303  bp of noncod- 
ing sequence (Figs. 2 A  and 3 A). Expression of this open 
reading frame in bacteria showed that it only encoded  a 
protein of 97 kD indicating that sequence was missing at the 
5' end. 
The missing sequence was obtained using the 5'-rapid am- 
plification of cDNA end (RACE) protocol (see Materials 
and  Methods).  An  open  reading frame calculated  to  be 
104 kD (912 amino acids) was obtained when the 5'-RACE 
fragment was combined with 3.5-kbp fragment (Fig. 2 A, 
Full length fragment).  This was checked by coupled tran- 
scription/translation.  As shown in Fig. 2 B, the molecular 
weight of the translated product (lane 3) was identical to 
that of authentic GM130 (lane 1) showing that this cDNA 
encoded full length GM130. 
Antibody was also raised to a 97-kD recombinant frag- 
ment of GM130 and was shown to recognize the same pro- 
tein as the antibody to the  17-kD fragment (Fig. 2  C, cf. 
lanes 1 and 3). Both antibodies recognized the same pro- 
tein in human (lanes 2  and 4)  as well as rat cell extracts 
(lanes 1 and 3). Minor bands seen at 120,  116,  83,  and 80 
kD  were  either  degradation  products  or  homologues  of 
GM130 (see Discussion). 
The Sequence and Structural Analysis of GMl30 
The complete sequence of the cDNA and deduced amino 
acid sequence are shown in Fig. 3 A. A plot of hydrophilic- 
ity showed that there was no classical signal sequence nor 
was there a stretch of hydrophobic and neutral amino ac- 
ids sufficient in length to span the lipid bilayer (Fig. 3 B). 
Strikingly, the entire central part of the protein had a high 
probability of assuming a coiled-coil structure (Fig. 3 C). 
There were, however, several interruptions suggesting that 
GM130  is a  rod-like protein with several joints.  Coiled- 
coil structures imply oligomerization of the protein, a pre- 
diction borne out by biochemical experiments (see below). 
The PROSITE Dictionary of Protein Sites and Patterns 
(Release 12.2)  revealed 16 casein kinase II phosphoryla- 
tion sites, 7 protein kinase C  phosphorylation sites, and 2 
tyrosine kinase phosphorylation sites. There were also two 
Figure 3.  Sequence and structural analysis of GM130. (A) Nucleotide and deduced amino acid sequence of GM130. Note the two gene 
specific primers used for 5'-RACE, the 5' and 3' end of the 17-kD fragment, the 5' end of the 97-kD fragment and the BsrGI site used to 
construct the full-length fragment. These sequence data are available from GenBank/EMBL/DDBJ under accession number U35022. 
(B) Hydrophilicity plot of GM130. Note the absence of any hydrophobic regions that could function as a signal or a transmembrane se- 
quence. (C) The predicted coiled-coil structure shows that the central part of GM130 is likely to be a coiled-coil. (D) Comparison of the 
amino acid sequence of GM130 and golgin-95. The COOH-terminal region of GM130 is 76.3% identical and 85.5% similar to golgin-95. 
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~1~  .........  + .........  ÷ .........  + ........  + ............................  + ........  +  ........  ÷  900 
0  QIK  0  A  o  I~  ¥  ~  K  D  L  T  K  E  R  D  A  L  K  L  E  I~  Y  K  N  G  K  S  N 
~'.n~  of ~.sk]o~  Ire~ent  {97kD  frm~,ent) 
a,~C-~C  crc~eGeat  C.C~OA~C  TC Aa ~t  C':~aA~C.AC.~AAC'n'C  0A0  TCeTOO  TeOC  ~O~  A~  ~  AC aG ~  ~ 
S0I  .........  *  .........  *  .........  + ...... + ................  + .........  +  .....  + .........  ÷  990 
EDLRQQNS ELEEKLRVLVAEKAAAQ  LGAEE 
.... _~__~'~ o:LV?__'.  L__ 
99~  .........  ÷ ........ +  ...............  +  ............................  +  ........  +  .........  + io~o 
5Q  K  KLEMSELLLQQ  FS  SQS  EASGSNEQLQQ 
RAC£  primer #i 
GGC~'~C.~a%~(/~GC  T~2  AC.C  %"G~AGAC42  C ATG'PI~CAGCTGA'I~GA~  AC  ~C~  C A~  ~  ~AOAC~  TAC~ 
I081 .........  +  .........  +  .........  +  .........  +  .................  +  ..................  +  .........  ÷ 1170 
AM  EERAQ  I~ES  HVGQ  L~ES  LRQLQVERDQyA 
AG~CC~CA~A~ACA~AGA~AGA~A~A~C~GG~G~A 
I~7~  .........  •  .........  + .........  + .............................................  + .........  +  I~0 
ENLKOE  SAMWQQRVQQMA  EQVHA  LK  EE  KEQ 
462~ fragment  (17kD  £ra~ent) 
12~1  .........  ÷ .........  + ...................  ÷ ...................  + ........  + ....... + .......  +  1350 
GCCTTCAGAGGCCGAAGAC~TCCAGC.GAGAC~GCAGC  T~CAGAAGGAACTC-GAC~TCTGACGGGTCAGC~A~T 
136a  .........  + .........  ÷ .........  ÷ .........  ÷ ....... -  ........  + .........  ÷ .........  + ........  +  1~o 
PSEAEERLQGEVEQLQKELEGLTOQLRAQV 
Q  ONEELSH  LNREQEGRMLE  5ERZAQHWS  EO 
A  E  E  R  K  Q  I  L  E  S  M  Q  H  D  R  T  "~  I  S  R  A  L  S  O  N  R  E  L  K  E 
Q  LAELQNGFVRLTN  ENM  ET  TSALQS  R~  HVK 
•  ......  4 
~S2hlp  fra~men~  (17kD fragment) 
B 
C 
o  .~ 
-r 
o 
8 
i 
o.~ 
1oo  ~oo  ~oo 
D 
GMI30  297 
golgin95  1 
GMI30  347 
51 
397 
golgin95  i01 
447 
golgin95  151 
497 
1711  .........  + ..............................................................................  i~oo  go±gln~b 
K  E  L  A  K  K  L  n  E  L  Q  E  R  L  G  E  L  K  E  T  V  E  L  K  S  Q  E  A  Q  S 
TC  T~CAGGAGCAC~ GAGACCAG  TGCC  TCTCC  C  ACC  TCC  ACC  AG  TAC  CC  ~  C  TAC  C  AACACC  AC  'Ff  GACA~ TATGACCAC'CTGAC  GMI 30 
1801  ......... + .........  + ....... + .........  + ..................  -  ................  + ...... +  a89o 
h  O  E  Q  R  D  Q  C  L  S  H  L  Q  Q  Y  A  L  A  Y  Q  Q  H  L  T  A  Y  E  Q  L  T 
~~A~A~C~A~CC~A~A~G~A~ 
1891  .........  *  .........  + .........  + .........  + .........  + ..........  -  ........  + .........  + .........  *  19a0 
aEKEAL.K~LLLQrQLMOQLQHE~VQOKMA  GMI30 
AC.C  C~AS  A~C.GC  C  CGC  C  AG~ACC  "~AC-C.AGGCACAGC,  AC.C  GC  C  TAAAAGC  T~C,  CACC  CAC.~C  C  ~JL  CAGCTC  C  AA  CC  C  C  A~  ~AG 
1981 .........  ÷  .........  ÷  .........  ÷  .........  +  .................  _  ........  ÷  ......  ÷  .........  + 2070 
A  E  M  A  R  Q  E  L  Q  E  A  Q  E  R  L  K  A  S  S  Q  E  N  Q  Q  L  Q  A  Q  n  S 
C  C'I~  "FTC.GTC  C  TCC  ~GATATG  GACC  AGGAG  C.AGCAAGAC  GAGGAGGTI'C  C  TC  ACC  C  C  AG  TC'I~  AC  CATCC  CA  GAAGAC  ~  T 
2o7~.  .........  + .........  + .........  + .........  •  .........  •  ........  + ...................  +  ......  ÷  n6o  GM130 
L  L  V  L  p  G  E  D  M  D  Q  E  E  Q  D  E  E  V  P  Q  P  S  5  T  I  P  E  D  L  V 
CAGTAC'AGAGGC  TA'~ AA  TC-CAGCG  ATAGC  C  AGACC  "~C'AGGAAG  ACC  AC'GC  C  CG  ACTC  C  GAG  TCCA~  ~G  ~ A~A  golgin95  201 
2161  .........  + .........  *  .........  + .........  + .........  ÷ .........  ÷ ..................  .  .........  ÷  2250 
SREAMVAFCNAAIARAEEEQARLRVQLREQ 
GMI30  547  CJU~Se*CSTTCCCC.C.~C'nV,  C,C~T~Z'I'SX~AC~CCCAGTCCmU~C.C~.~~C~A~A 
KARCRSLAHLAAPVQSKLEKEAVVPRpMGD 
golgin95  244 
CTCTGTATC~G2~CAGGCCC  TACATCTACCCATC,3AGAA~AGAGCCGC~'pCCTGGAGGTCATGCAGGAGA~TGGA 
S  V  S  E  E  S  N  Q  A  L  "  V  A  M  E  K  L  Q  S  R  F  L  E  V  M  Q  E  K  V  E  GMI30  597 
C~AA(~  AC~  AC~  CATTCC  TGTATC  C  AG  C  TTTC  T~KGAC  &GACAC  TA~  AGAGTACA~C  C  C~  AC  C  A 
~i  .........  ÷ ......... +  .......  + .........  + ..........................  +  .........  + .........  ~o 
L  K  E  R  V  E  E  L  E  H  C  C  I  Q  L  S  G  E  T  D  ~'  Z  G  ~  Y  Z  A  Z  Y  O  golgin95  294 
2~AGAC~AGTC~C'~GC~OCCATT~AGAAGG~GAGTATA'~AGCCGGCTC~TCAGGACAA~GGAGA~T~ 
~  ...................  ÷ ...................................................................  ~zo  GM130  636 
N  Q  R  A  V  L  K  A  R  a  L  E  K  E  E  y  I  S  R  L  A  Q  D  K  E  E  M  K  V  K 
~TA~~  ~C G~A~BG~C~AG~CC  ~  golgin95  344 
L  L  E  L  Q  E  L  V  L  R  L  V  N  E  R  N  E  W  Q  G  K  F  L  A  V  S  Q  N  P  A 
GMI30  686  ~C~CC~CCACA~CCA~A~A~GG~CC~A~G~ACGA 
~701  .........  + .........  *  .........  ÷ .........  + ...........................  ÷  ........  +  .........  +  ~7~0 
v  ~  ~  ~  v  ~  r  a  s  Q  ~  r  ~  ~  ~  ~  Q  Q  G  ~  ~  ~  ~  v  s  ~  ~  D  ~  golgin95  394 
TACAGACC~CAAGGAGAC'GCAC'C'C.GTACCCGCTCCCCAGGAGAACCCCA~TC`CACAACAGATCATC`CA~TGAGATCCA 
~791  ......... .  ...................  +  .........  ÷  .........  *  ........  ÷ ..................  + .........  ÷  2880 
T  E  p  A  Q  G  E  A  G  V  p  A  p  Q  E  N  P  T  A  Q  e  I  M  O  L  L  R  E  I  Q  GMI30  736 
~CCCCA~A~C~C  ~TA~C~A~CCC~TACCG~A~CGACGA~T 
~$~  ...................................................................................  + ~97o  golgin95  444 
NpQERpGLGSNpCI  pFFYRADENDEVKI  MV 
TATAT~C~C~ACC~A~CA~G~CCACC~ACCCC~CA~AC~TA~C~TA  GMI 30  786 
2971 .........  +  .........  +  .........  +  .....  +  ........  +  .........  ÷  ....  +  .........  ÷  ........  ~ 3860 
3o6~ ATAAC~A~A~CCC~C~CTCCAc~TAC~CTCA~TTC~TAC'AGTc=C~P~CCTCCCATGCACATAC'CcCTC~TCCC~A  ~  golgin95  494 
3151  ~AT~GT~G~~O~A~A~T~A~G~C 
3~41 AC  ACTGGGCTAC  ATC,  AGACC  C'IGTC  ~C  C  AAAAGA~ TATA~FP.%AT~TAC  AAAC  TOGTAC  AGG  TCTC  C~ 
353~.  AGCC  AGOGCAGTTTTAC CTTGTAAACTCC "f  GGTAG~GC  AC  C~  TCAG  TGA'ITGAC-CAGACTG  TC,  C  TC~  ~  A  GMI30  836 
]~1 c  en'CTCAC  ~  TCAG  ~  ~.C-CC*.C'r~C~CAS.'U~CAG  ~^GCCnV~CXrC~C  CAC~S.~<~C  ^  TG 
3511 GGCTC.GTC,  C.AT~  G~CC  TAGCA~'I'CA£-CACCGCTCAGGAT'FI'T'/~  AC  CATCTCAG  TC  G  ~AC  CCTC  C~I'TCCC  TC  CCC  AACC  C  CA~ 
360~. T  ATATTC.ATT~'F'~-ATATA~'£TACAT2~-CCCGGGCTAACCCI~GAA£TCACTACAG'A~C~AC~T  golgin95  544 
~9~ CCe~C~AU~n~&'~SCT~C~C~r-ACTCT~C¢~C'~S~'I~TCCeC~GCACT~¢CeSeC  CTTrC~C  ~T~ ~ 
3781 ~CC~AC~C~A~CA~A~A~~G~A~T 
38";1 C  e  CCGOGCAG~  ACTCCCTCAC~a* G~CATCCCACTTAC~  C  ATC  TCTelT,  AOGC  AC~  CAGGGAAAG  TC~G  GMI30  886 
3961 TACCATTC~GGCC  TTATGAC  AATT~AAC  TA~GC  CAAGCAGGAC  AGAGG~ GG~  TTCCCCTC~C~T 
4051 GTACATAT'DSTACC  T~AC  TATTTTGTATA~'TC  TGGGGTAGGGACAC  C  C  ~  TATCATAG~GG~C.GAGC~AAG  ~-'C~C  A  G 
4141 AGCTTCTAATAATCA~TCC~GAAACTTATTTA~F1GGTAGTGTTAG~TCAC.GACA~AGGCGGAGACGTC'GTTG~ACC~  golgin95  594 
•  ~1  .rc.c^c,  cTcc,r~errtcm,~c~a,-m~rr^~ax~c~'r~rAcc 4~0 
/- 
.LI 
~0  500  600  ,~a  ,6o  9~0  I 
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lIIlllIIIillilllll.:llll:l:lll..lllll  I  ....... ll:i 
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ll:illll  lilll:--lllllll  -.l.:lllilllrlllIl:lll.J 
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Nakamura  et al. Characterization  of GM130  1719 predicted  N-glycosylation  sites  but  these  would  not  be 
used since the protein is cytoplasmic (see below). 
A  search of the protein sequence Database (GenBank: 
Release 89.0; EMBL: Release 42.0) revealed homology to 
a human protein, golgin-95 which was identified as the an- 
tigen in an autoimmune disease, Sj6gren's syndrome (Fritz- 
ler et al., 1993).  As shown in Fig. 3 D, the homology was 
restricted to the COOH-terminal 616 residues of GM130. 
Sequence identity was 76.3% and the similarity was 85.5%. 
Golgin-95  lacked  the  NH2-terminal  296  amino  acids  of 
GM130.  In addition,  GM130 has one short insertion and 
two short deletions when compared to golgin-95. 
No other proteins were found to be highly homologous 
to  GM130.  Many proteins with predicted coiled-coil do- 
mains were found to be weakly similar to GM130 (~20% 
identity, ~50% similarity), but these similarities were mar- 
ginal and varied depending on the search algorithm used 
(FASTA,  BLAST,  and  SHARQ:  Pearson  and  Lipman, 
1988; Altschul et al., 1990; Collins and Coulson, 1990). The 
regions of similarity were restricted to the coiled-coil do- 
main of GM130 and were scattered throughout the mole- 
cule. The most similar proteins included giantin/GCP372, 
which is also a  Golgi resident protein (Seelig et al., 1994; 
Sohda et al., 1994); involucrins, which are part of the plasma 
membrane skeleton in epidermis (Eckert and Green, 1986); 
Usolp, a yeast protein essential for ER to Golgi transport 
(Nakajima et al., 1991); various myosin heavy chains (Sun 
and  Chantler,  1992);  p150  atued, a  subunit  of the  dynactin 
complex (Holzbaur et al., 1991); NuMA, a protein involved 
in nuclear structure, spindle assembly, and nuclear re-for- 
mation (Maekawa and Kuriyama, 1993; Yang et al., 1992); 
and CENP-E, a putative centromeric motor protein (Yen 
et  al.,  1992).  Though  some  of these  might  suggest  that 
GM130 is involved in performing mechanical work, there 
were no predicted binding sites for either ATP or GTP. 
Topology  of GM130 
GM130 is a peripheral protein strongly associated with Golgl 
membranes. As shown in Fig. 4  (top),  all of the  GM130 
sediments with  Golgi membranes (lanes 1  and 2)  and  it 
cannot be removed with 1 M KC1 (lanes 3 and 4). The pro- 
tein  could  only be removed by treatment  with  high  pH 
(lanes 5 and 6), 6 M urea (lanes 7 and 8), or treatment with 
Triton X-114 (lanes 9-11).  GM130 was entirely extracted 
into the aqueous phase (lane 9) after phase partitioning of 
Triton X-114. al,3-1,6-mannosidase II (Man II), a resident 
membrane enzyme was used as a positive control in all of 
these experiments. As shown in Fig. 4 (bottom), it resisted 
all  extraction conditions  except Triton X-114.  The  pres- 
ence of about 30%  of Man II in the aqueous phase after 
phase partitioning probably reflects the large lumenal do- 
main of this protein (lane 9, bottom; Moremen et al., 1991). 
In addition, ~10% of Man II remained in an insoluble pre- 
cipitate (lane 11, bottom). 
GM130 is located on the cytoplasmic side of Golgi mem- 
branes (Fig. 5). When Golgi membranes were treated with 
increasing  concentrations  of chymotrypsin,  GM130  was 
degraded at the lowest concentration used (0.25  mg/ml). A 
doublet  of  about  82-kD  appeared  and  disappeared  at 
higher concentrations of chymotrypsin. In contrast, concen- 
trations of chymotrypsin up to 1.0 mg/ml had no effect on 
Man II which only has 5 amino acids exposed to the cyto- 
plasm (Moremen and Robbins, 1991). 
GM130  was present  in  the  Golgi matrix  fraction  pre- 
pared by treating Golgi membranes with 2% Triton X-100, 
followed by 150  mM NaC1.  A  protease inhibitor cocktail 
had to be added to prevent degradation of GM130 and this 
had the effect of preventing complete removal of Man II 
from the final matrix fraction that was observed previously 
(Slusarewicz et al., 1994b). As shown in Table I, >80% of 
Man  II and  GM130  remained  in  the  Triton  pellet  but 
whereas only ~20% of the Man II remained in the matrix 
Figure 4.  Association  of GM130 with Golgi membranes. Purified 
Golgi membranes were treated with phosphate buffer (lanes  1 
and 2), 1 M KC1 (lanes 3 and 4), 0.2 M sodium carbonate, pH 11 
(lanes 5 and 6), or 6 M urea (lanes 7 and 8) for 30 min on ice, and 
then separated into a supernatant (S) or a pellet (P) fraction  by 
centrifugation  at 4°C, 100,000 g  for 10 min.  Golgi  membranes 
were also treated with Triton X-114 for 10 min on ice, centrifuged 
at 4°C to remove insoluble aggregates (P, lane 11) and then phase 
separated at 37°C yielding an aqueous (Aq, lane 9) or detergent 
(D, lane 10) phase. Samples were fractionated on a 6-15% gradi- 
ent SDS-polyacrylamide gel and Western blotted using antise- 
rum to Man II (bottom) or a 17-kD fragment of GM130 (top). 
Figure 5.  Sensitivity of GM130 to chymotrypsin.  Rat liver Golgi 
membranes were treated with 0 (lanes 1, 5, 9 and 13), 0.25 (lanes 
2, 6, 10, and 14), 0.5 (lanes 3, 7, 11, and 15), or 1.0 (lanes 4, 8, 12, 
and 16) mg/ml chymotrypsin  for 30 min on ice. After quenching 
with 2 mM PMSF (final concentration), the membranes were re- 
isolated by high speed centrifugation.  The pellets (lanes 5-8 and 
13-16)  and supernatants (lanes 1-4 and 9-12) were fractionated 
on a 6-15 % SDS-polyacrylamide gradient gel and Western blot- 
ted using polyclonal antisera either to Man II (lanes 9-16; dot on 
the right) or the 17-kD fragment of GM130 (lanes 1-8; upper dot 
on the left). Note the degradation product of GM130 in the super- 
natant at 0.25 mg/ml chymotrypsin (lane 2, lower dot on the left). 
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Fraction  Man II  GM 130 
Triton pellet  87.9 _+ 0.4%  80.2 --- 2.1% 
Golgi matrix  20.5 -+ 2.4%  36.7 _+ 0.9% 
Purified rat liver Golgi membranes were extracted sequentially with 2% Triton and 
150 mM NaCl yielding a Triton pellet and then a Golgi matrix fraction. The percent- 
age yield of Man II and GM130 in each fraction was determined by enzyme activity or 
Western blotting respectively. Results are presented as the mean of three experiments 
-+ SEM. 
fraction, ,'-~37% of the GM130 was found there (Table I). 
This shows that GM130 is enriched in the matrix fraction 
when compared to resident Golgi enzymes such as Man II 
but that  a  considerable  fraction was solubilized by treat- 
ment with 150 mM salt. 
The size of GM130 after complete solubilization of the 
matrix in 500 mM NaC1 was determined by gel filtration 
on a Superose 6 column. Man II was also completely solu- 
bilized and ran, as expected, as a homodimer of about 250 
kD (Fig. 6, lower panel, peaks in lanes 9 and 10; Moremen 
et al.,  1991).  GM130, in contrast, ran at the position of a 
protein with a molecular weight of about 1,000  kD (upper 
panel,  lanes 4 and 5). This is most easily explained by the 
formation  of  homo-oligomers  or  hetero-oligomers  with 
those proteins that appear to co-elute (data not shown). 
Cellular Localization 
The localization of GM130 was mapped by immunofluo- 
rescence microscopy using a series of HeLa cell lines each 
stably expressing a  Golgi marker restricted to one part of 
the organelle. The cell lines expressing epitope-tagged ver- 
sions  of the  medial-/trans-Golgi  enzyme,  13-1,2-N-acetyl- 
glucosaminyltransferase I (NAGT I), and the trans-Golgi/ 
TGN enzyme, et2,6-sialyltransferase (SialylT), have been 
described previously (Nilsson et al., 1993; Rabouille et al., 
1995).  A  HeLa celt line  stably expressing the  t-SNARE, 
syntaxin5 (Bennett et al., 1993), was generated in the same 
way using the  myc-tagged protein  (Banfield  et al.,  1994) 
and characterized by immuno-EM. Most of the syntaxin5 
was found in  the  CGN, comprising an  extensive tubulo- 
vesicular network  abutting  the  cis-face  of the  stack,  the 
rest being present in the stacked cisternae, most often the 
cis-most  one. This is almost exactly the same distribution 
as was found for the  transiently expressed protein  (Ban- 
Figure 6.  Gel filtration  of GM130. The Golgi matrix, solubilized 
in 500 mM NaC1, was fractionated by gel filtration  and the frac- 
tions subjected  to SDS-PAGE followed by Western blotting  us- 
ing antisera either to Man II (bottom) or the 17-kD fragment of 
GM130 (top). Positions of the size markers are shown at the top. 
field et al., 1994). 
These cell lines were double labeled using monoclonal 
antibodies to the tagged Golgi markers and affinity-purified 
polyclonal antibodies  to  the  17-kD  fragment of GM130. 
As shown in Fig. 7, GM130 partially co-localized with Sia- 
lylT (cf. Fig. 7, A  and B) and even more so with NAGT I 
(cf. Fig. 7, C and D). However, the best co-localization was 
obtained  with the  CGN  marker, syntaxin5  (cf. Fig.  7,  E 
and F). Antibody to p53 was also used. This labels those 
compartments involved in transport of cargo between the 
ER and the Golgi stack (Schweizer et al., 1990). As shown 
in Fig. 7, G and H, GM130 almost always co-localized with 
that part of the p53 resident in the CGN but not with the 
peripheral punctate structures (arrowheads) that are likely 
involved in cargo transport. 
Experiments  with  BFA  provided  additional  evidence 
for the location of GM130. Both NAGT I and SialylT were 
redistributed to the ER in the presence of BFA (data not 
shown)  but  syntaxin5  and  p53  were  found  in  dispersed, 
punctate  structures  (Fig.  7,  J  and  L).  GM130  was  also 
found in these structures, co-localizing almost completely 
with syntaxin5 (Fig. 7, I and J) and substantially with p53 
(Fig. 7,  K  and L). These effects were reversed within 30 
min of removing the drug (data not shown). 
The location of GM130 was also examined by immuno- 
EM.  In NRK  cells,  labeling for GM130  was found  over 
one or two cisternae on one side of the stack and over an 
associated network (Fig. 8, A-C). Approximately one third 
of the labeling was found over the network, and two-thirds 
over the stacked cisternae. This labeling was mostly oppo- 
site the side that had the unique morphology of the TGN 
comprising extensive networks of tubules and many bud- 
ding profiles, some coated with clathrin. This was confirmed 
by  double-labeling  using  HeLa  cells  expressing  epitope 
tagged SialylT. As shown in Fig. 8  (D-F), most of the la- 
beling for GM130 was found on the side opposite to that 
labeled for SialylT. The level of labeling was low because 
of poor cross-reactivity of the antibody but quantification 
confirmed the location of GM130 showing that 79  -  2% 
(SEM) of the gold particles (total  =  66) were present on 
the cis-side of the Golgi apparatus. 
Much of the cisternal labeling for GM130 was found on 
the crY-face  of the c/s-most cisterna (Fig. 8, A-C, arrowheads) 
and some was found between the cis-most  cisternae (Fig. 
8, A-C, arrows). Since GM130 is a peripheral, cytoplasmic 
protein  by biochemical  criteria,  this  shows  that  at  least 
some of this protein is located in the intercisternal space. 
Discussion 
GM130  has  many of the  properties expected of a  struc- 
tural protein of the Golgi apparatus. It is a  tightly bound 
peripheral membrane protein that can be released by high 
pH, urea and Triton but not by high salt (Fig. 4).  In the 
presence of both detergent and high salt it runs as a large 
oligomer that is likely to contain other structural proteins 
(Fig. 6). It is present on the cytoplasmic side of the mem- 
brane because it is accessible to digestion by proteases un- 
der conditions where Man II is not (Fig. 5). Sequence anal- 
ysis corroborated these results showing that there was no 
putative signal sequence nor membrane-spanning domain 
(Fig. 3 B). Structural analysis predicted a jointed, rod-like 
Nakamura et al. Characterization of GM130  1721 The Journal of Cell Biology, Volume 131,  1995  1722 Figure 7.  Localization of GM130 by immunofluorescence microscopy. HeLa cells stably transfected with epitope-tagged SialylT (A and 
B), NAGT I (C, D, G, H, K, and L), or Syntaxin5 (E, F,/, and J) were fixed, permeabilized, and double labeled with antibodies to the 
17-kD fragment of GM130 (A, C, E, G, 1, and K) and either antibodies to the VSV-G tag (P5D4: B), the myc tag (9El0: D, F, and J), or 
p53 (H and L). Secondary antibodies were coupled to FITC (A, C, F, G, J and K) or Texas red (B, D, E, H,/, and L). In l-L, cells were 
pre-treated with BFA for 30 min before fixation. Small arrows indicate areas where both markers co-localize, whereas large arrows (A, 
B, G, and H) and arrowheads (G and H) indicate differences in the staining patterns. Bar, 10 ixm. 
structure  throughout the  central  region  of the  molecule 
(Fig.  3  C).  Coiled-coils are characteristic of many struc- 
tural proteins with which GM130 shares weak homology. 
The presence of so many different types of phosphoryla- 
tion site suggests that its structure might be regulated in 
vivo though at present we have no evidence that this is the 
case. GM130 appears to be a permanent resident of Golgi 
membranes since preliminary experiments show that there 
is little if any of this protein in HeLa cytosols at any stage 
of the  cell cycle. It is,  therefore,  more likely to act as a 
membrane scaffold than an  active participant in the for- 
mation or fusion of transport vesicles (Rothman, 1994). 
The COOH-terminal part of rat GM130 was highly ho- 
mologous to a 95-kD human Golgi auto-antigen, golgin-95 
(Fritzler  et  al.,  1993).  One  possible  explanation  is  that 
GM130 and golgin-95 are the products of alternative splic- 
ing or initiation of translation from different start sites. The 
two antibodies used in these experiments were raised to 
regions that would be common to both proteins. The anti- 
body to rat GM130 recognizes a protein of the same mo- 
lecular weight in HeLa cells.  It does not, however, recog- 
nize a protein of 95 kD in either NRK or HeLa cells. This 
could be explained by the fact that Fritzler and colleagues 
(1993)  did not use HeLa cells for their  analyses and the 
molecular weight  of golgin-95 might depend  on the cell 
line.  Minor proteins with molecular weights other than 95 
kD were found in HeLa cells  and one of these might be 
the HeLa cell isoform of golgin-95. However, exactly the 
same pattern of minor bands was seen using NRK cells ar- 
guing that these minor bands are degradation products of 
GM130 and not cell type specific variants of golgin-95. The 
alternative  and more interesting  explanation for the  ho- 
mology between GM130 and golgin-95 is that they might 
be different members of a  family of proteins involved in 
structural maintenance of the Golgi apparatus. This is sup- 
ported by the fact that several deletions had to be intro- 
duced to align the rat and human sequences. Experiments 
are in progress to look for other family members. 
The location of GM130, on the cis-side of the Golgi ap- 
paratus was initially somewhat surprising.  The detergent 
and salt resistant matrix had been characterized by its bind- 
ing of medial-/trans-Golgi  resident  enzymes (Slusarewicz 
et  al.,  1994b).  However,  re-examination  of the  original 
binding data showed that whereas trans-Golgi/TGN mark- 
ers  were  only present  at  10-15%  of their  original level, 
CGN  markers  were  present  at  higher  levels  (20-35%). 
This suggests that elements of a cis-matrix are also present 
in the  isolated fraction and this would help explain  why 
antibodies were raised to GM130. 
These  antibodies  were  used  to  localize  GM130  using 
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by immuno-EM.  (A-C)  Frozen 
sections of NRK  cells were  la- 
beled  with  antibodies  to  the 
97-kD  fragment of GM130 fol- 
lowed by goat anti-rabbit anti- 
bodies  coupled  to  10  nm  gold 
particles.  Labeling  was  found 
over  intercisternal  regions  (ar- 
rows), cisternae and tubular struc- 
tures  (arrowheads)  on  the  cis- 
side  of the  Golgi stack.  (D-F) 
Frozen sections of HeLa cells sta- 
bly expressing a  VSV-G-tagged 
SialylT were double labeled with 
polyclonal  antibodies  to  the 
97-kD  fragment  of GM130  (10 
nm gold) and P5D4 monoclonal 
antibodies to the VSV-G tag (5 
nm  gold).  Labeling for GM130 
(open arrowheads) was restricted 
to the side of the Golgi stack op- 
posite to that which was labeled 
for the trans-GolgifFGN marker, 
SialylT (arrows). G, Golgi stack; 
N,  nuclear  envelope;  T,  TGN. 
Bars, 200 nm. 
both  immunofluorescence  microscopy  and  immuno-EM. 
GM130  co-localized only  partially with  the  trans-Golgi/ 
TGN marker, SialylT, and more so with the medial-/trans- 
Golgi marker, NAGT I, but the best overlap was obtained 
with the CGN marker, syntaxin5. It also co-localized with 
that portion of p53 that is thought  to reside in the  CGN. 
Localization to the CGN  was supported by the  action of 
BFA. This drug redistributes most Golgi enzymes to the 
ER  but not those  markers present in  the  CGN  (Lippin- 
cott-Schwartz  et  al.,  1990;  Saraste  and  Svensson,  1991; 
Tang et al., 1993; Alcade et al., 1994; Rios et al., 1994; Sub- 
ramaniam et  al., 1995).  In the presence  of BFA, GM130 
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co-localized almost completely with syntaxin5 and partially 
with p53. Immuno-EM confirmed the location of GM130. 
It was found in the CGN and also in one or two cisternae 
on the cis-side of the Golgi apparatus. 
Of the putative Golgi structural proteins, GM130 most 
closely resembles,  in location and behavior, p210, a Golgi 
auto-antigen (Rios et al., 1994). It will be interesting to see 
whether  this  protein  is  present  in the  same  complex  as 
GM130. The other large Golgi auto-antigen, with a molec- 
ular weight of 230 kD, has been localized to the opposite 
side of the Golgi apparatus, the TGN (Kooy et al., 1992). 
This raises the interesting possibility of a family of struc- 
tural proteins that might be  involved in establishing  the 
polarity of the Golgi stack. The sequence of these two pro- 
teins should help establish the validity of this suggestion. 
In conclusion we have identified a structural protein of 
the Golgi matrix that is likely involved in the organization 
of the cis-Golgi apparatus. Further analysis of the hetero- 
oligomer generated by detergent and high salt extraction 
should help us to identify other proteins needed to main- 
tain the architecture of this organelle. 
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